Evidence map›Paper›PMID 29406607›Full record

Trial reportJournal of diabetes investigation2018

Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early-stage type 2 diabetes.

Hidenori Hirukawa, Mitsuru Hashiramoto, Yukio Tanizawa, Kohei Kaku, Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti-Atherosclerosis in Japan (PREVENT-J) study group

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hidenori HirukawaDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Okayama, Japan.ORCID http://orcid.org/0000-0002-4826-2574
Mitsuru HashiramotoMitsuru Clinic, Amagasaki, Japan.
Yukio TanizawaDivision of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.ORCID http://orcid.org/0000-0002-4742-8245
Kohei KakuDivision of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Pioglitazone and Sulfonylurea Remission from Type 2 Diabetes Mellitus and Anti-Atherosclerosis in Japan (PREVENT-J) study group
Kawasaki Medical School · JPMitsui (Japan) · JPYamaguchi University · JP

Funding

Japan Cardiovascular Research Foundation 067
6 · The paper itself

Abstract

AIMS/

introductionTo assess whether intervention with oral antidiabetic drug in Japanese patients with the early stage of type 2 diabetes could provide a significant remission of the disease process. MATERIALS AND

methodsPatients with diabetes duration <5 years were randomized to the lifestyle modification (LFS), pioglitazone (PIO) or sulfonylurea (SU) treatment group. In phase 1 as the on-treatment period and in phase 2 as the off-treatment period, the duration that glycated hemoglobin (HbA1c) was maintained at less than the target was compared among groups.

resultsA total of 278 patients were assigned to LFS (n = 84), PIO (n = 101) and SU (n = 93), and 212 patients completed phase 1. The number of patients that dropped out because of HbA1c elevation was larger in the LFS group, and the duration of HbA1c being maintained at <7.9% was longer in the SU group than the other groups. The duration of HbA1c being maintained at <7.4% in phase 2 was significantly shorter in the SU group than in the other groups. The proportion of patients who achieved HbA1c <6.9% or 6.2% at the end of phase 1 was obviously less in the LFS group than other groups. The duration of HbA1c being maintained at <6.2% in phase 2 was longer in the PIO group than other groups, although not significant statistically. An increase in serum adiponectin and decreases in high-sensitivity C-reactive protein and homeostatic model assessment of insulin resistance were shown in patients treated with PIO, but not LFS and SU, in phase 1, but were canceled in the drug-off phase 2 period.

conclusionsPIO treatment provided a prolonged remission of hyperglycemia after stopping the dosage in patients with the early stage of type 2 diabetes.

Indexed as

Administration, OralDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansHyperglycemiaHypoglycemic AgentsJapanMaleMiddle AgedProspective StudiesRemission InductionGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsRemission of hyperglycemiaType 2 diabetesWithdrawal of oral antidiabetic drugs

Identifiers

PMID29406607
PMCPMC6123043
OpenAlexW2791509656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.